SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
March, 2020
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x | Form 40-F ¨ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ | No x |
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit Number |
Description of Exhibits | |
99.1 | Press Release dated March 17, 2020 for Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDY’S LABORATORIES LIMITED (Registrant) | |||
Date: March 17, 2020 | By: | /s/ Sandeep Poddar | |
Name: | Sandeep Poddar | ||
Title: | Company Secretary |
Exhibit 99.1
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com |
March 17, 2020
Corporate Relationship Department | National Stock Exchange of India Ltd. |
BSE Limited | “Exchange Plaza” |
Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
Mumbai – 400 001 | Mumbai – 400 051 |
Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
22722037 / 22722039 | 26598238 |
Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Dear Sirs,
Sub: Press Release
Please find enclosed a Press Release on “Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market.”
This is for your information.
With regards,
/s/ Sandeep Poddar | |
Sandeep Poddar | |
Company Secretary |
Encl: As above
CC:- New York Stock Exchange Inc.(Stock Code: RDY)
Classification | PUBLIC
CONTACT | ||
DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. |
AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) |
DEEP GHATAK deepghatak@drreddys.com |
Dr. Reddy's Laboratories announces the
launch of
Ziprasidone Mesylate for Injection in the U.S. Market
Hyderabad, India, March 17, 2020 | For Immediate Release |
Hyderabad, India and Princeton, NJ, USA. March 17, 2020— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Ziprasidone Mesylate for Injection, 20 mg (base)/mL Single-dose Vials, the therapeutic generic equivalent of Geodon® (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA).
“We’re pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy,” explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment.”
The Geodon® brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone mesylate for injection is not approved for the treatment of patients with Dementia-Related Psychosis.
|
Please see full Prescribing Information including boxed warning.
https://www.drreddys.com/pi/ziprasidone-20mg.pdf
Geodon® is a trademark of Pfizer
*IQIA Retail and Non-Retail MAT January 2020 RDY-0220-275 |
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues. The company assumes no obligation to update any information contained herein.
)8)#_ +MF
MP$$5^"UOM)<2.4G)&*DIS0W'W:VUX:'.*,K,4RIOI.'9/"I J>/-+"",
QI(
MW.PT-05 ZDC,B#6;&OG(/PI6G[5 7IO=4SGQR#ZJ-NX_[>[CK5\G*;?86/5@
M4:/AC:08T-*84K3M.61C6]A;'3?,FT>Y/)KK!(*/ , ?[?9M7O'V-[5:2[%
MV^K-/U;G;&6CH[GK.?\ K73EG4&$N,9V%TC1&!TPRFZJG9CEEC!E@N(OYE&T
M=7\U=_V?;LW473H?%57=JZ3)[>[B_G0L:?\ I_W';^U5C?M/,.A1TY^72D-9
MF+S?'*3<5BUOIB=9K)^;L]>K&D8>@N?SB=8C^EZ]7E)AT8OY4Y-VD0>T0*)K
M=E6H9?JA[P:?%Q YNELCRZ.XO&$?(;@87SCAAFG$43:[XV./$"B.8YWF$6('
MH1,!3#^SOHJ$L2=1A9(7S=^62?(#'$=Q"8.>P@]H;J^JG1FH=7Y'DK\@_37#[/,
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M@\ /U/SB^I3Z<'Y-)<=P] 0%V3.)DO+1@J;